GSK, Vivalis get green light to test new vax tech

The push to get better, faster vaccine technology in place took a step forward with the news that France's Vivalis and GlaxoSmithKline have won FDA approval to begin clinical trials of a new flu jab using duck stem cell line EB66 technology. Vivalis says the regulatory green light could pave the way to an approval for the first such new vaccine as early as 2015. Story

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.